Several studies have validated that SHMT2 expression is elevated in breast cancer, intrahepatic cholangiocarcinoma and gastric cancer, and high levels of SHMT2 are associated with poor prognosis of patients[15, 30, 31]. The gene discussed is SHMT2; the disease is breast cancer.